Editorial
Oncogene alterations in non-small cell lung cancer—have we MET a new target?
Translational Lung Cancer Research
2022;
11
(10)
:1977-1981
.
(31 October 2022)
Cellular senescence and lung cancer prognosis
Translational Lung Cancer Research
2022;
11
(10)
:1982-1987
.
(31 October 2022)
Lung function impairment in lung cancer screening: discordance between risk and screening outcomes when looking through a PRISm
Translational Lung Cancer Research
2022;
11
(10)
:1988-1994
.
(31 October 2022)
Original Article
Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients
Translational Lung Cancer Research
2022;
11
(10)
:1995-2009
.
(31 October 2022)
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
Translational Lung Cancer Research
2022;
11
(10)
:2010-2021
.
(31 October 2022)
Fusion gene recurrence in non-small cell lung cancers and its association with cigarette smoke exposure
Translational Lung Cancer Research
2022;
11
(10)
:2022-2039
.
(31 October 2022)
Cannabinoid receptor 2 expression in early-stage non-small cell lung cancers identifies patients with good prognosis and longer survival
Translational Lung Cancer Research
2022;
11
(10)
:2040-2050
.
(31 October 2022)
FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer
Translational Lung Cancer Research
2022;
11
(10)
:2051-2063
.
(31 October 2022)
Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients
Translational Lung Cancer Research
2022;
11
(10)
:2064-2078
.
(31 October 2022)
A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma
Translational Lung Cancer Research
2022;
11
(10)
:2079-2093
.
(31 October 2022)
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA
Translational Lung Cancer Research
2022;
11
(10)
:2094-2110
.
(31 October 2022)
The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study
Translational Lung Cancer Research
2022;
11
(10)
:2111-2124
.
(31 October 2022)
Uniportal video-assisted thoracic surgery basal segmentectomy: a single-center retrospective cohort study
Translational Lung Cancer Research
2022;
11
(10)
:2125-2135
.
(31 October 2022)
KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China
Translational Lung Cancer Research
2022;
11
(10)
:2136-2147
.
(31 October 2022)
Review Article
Multiple mutations in the EGFR gene in lung cancer: a systematic review
Translational Lung Cancer Research
2022;
11
(10)
:2148-2163
.
(31 October 2022)
Letter to the Editor
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
Translational Lung Cancer Research
2022;
11
(10)
:2164-2166
.
(31 October 2022)
